|D004700||Endocrine System Diseases NIH||0.71|
|D044882||Glucose Metabolism Disorders NIH||0.58|
|D008659||Metabolic Diseases NIH||0.50|
There is one clinical trial.
This study evaluates the retinal vascular features using optical coherence tomography angiography in patients that have been affected by COVID-19.
Description: The parameter analyzed by optical coherence tomography angiography was: retinal vessel densityMeasure: The measurements of retinal features in patients with previous diagnosis of COVID19, using optical coherence tomography angiography. Time: one month
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports